These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 27288996)

  • 1. Will dengue vaccination be cost-effective for Argentina? Reply to letter by Urueña et al. regarding "Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission".
    Orellano PW; Salomon OD
    Vaccine; 2016 Jun; 34(28):3221. PubMed ID: 27288996
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Orellano et al. regarding cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission.
    Urueña A; Vizzotti C; San Juan JA
    Vaccine; 2016 Jun; 34(28):3222. PubMed ID: 27288997
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission.
    Orellano PW; Reynoso JI; Stahl HC; Salomon OD
    Vaccine; 2016 Jan; 34(5):616-621. PubMed ID: 26724542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dengue vaccines. A reality for Argentina?].
    Orellano PW; Salomón OD
    Medicina (B Aires); 2016; 76(2):98-102. PubMed ID: 27028058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Dengue Vaccination Programs in Brazil.
    Shim E
    Am J Trop Med Hyg; 2017 May; 96(5):1227-1234. PubMed ID: 28500811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current issues in the economics of vaccination against dengue.
    Tozan Y
    Expert Rev Vaccines; 2016; 15(4):519-28. PubMed ID: 26642099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of a pediatric dengue vaccine.
    Shepard DS; Suaya JA; Halstead SB; Nathan MB; Gubler DJ; Mahoney RT; Wang DN; Meltzer MI
    Vaccine; 2004 Mar; 22(9-10):1275-80. PubMed ID: 15003657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling.
    Shafie AA; Yeo HY; Coudeville L; Steinberg L; Gill BS; Jahis R; Amar-Singh Hss
    Pharmacoeconomics; 2017 May; 35(5):575-589. PubMed ID: 28205150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dengue reemergence in Argentina.
    Avilés G; Rangeón G; Vorndam V; Briones A; Baroni P; Enria D; Sabattini MS
    Emerg Infect Dis; 1999; 5(4):575-8. PubMed ID: 10460181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
    Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
    Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is discussion of dengue vaccination for the 2016 Olympics necessary?: Authors' reply.
    Halstead SB; Aguiar M
    Lancet; 2016 Oct; 388(10054):1881-1882. PubMed ID: 27751396
    [No Abstract]   [Full Text] [Related]  

  • 12. Laboratory surveillance of dengue in Argentina, 1995-2001.
    Avilés G; Paz MV; Rangeon G; Ranaivoarisoa MY; Verzeri N; Roginski S; Baroni P; Enria D
    Emerg Infect Dis; 2003 Jun; 9(6):738-42. PubMed ID: 12781019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Outbreak of Dengue-2 virus in Salta, Argentina, 1988].
    Avilés G; Rangeon G; Baroni P; Paz V; Monteros M; Sartini JL; Enria D
    Medicina (B Aires); 2000; 60(6):875-9. PubMed ID: 11436695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevalence of dengue in a risk area in Argentina].
    Alonso JM; Risso A; Mangiaterra M; Guillerón C; Gorodner J
    Medicina (B Aires); 1987; 47(5):551. PubMed ID: 3504994
    [No Abstract]   [Full Text] [Related]  

  • 15. Dengue vaccine: a valuable asset for the future.
    Jindal H; Bhatt B; Malik JS; S K S
    Hum Vaccin Immunother; 2014; 10(8):2245-6. PubMed ID: 25424928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic analysis of dengue virus type 3 isolated in Buenos Aires, Argentina.
    Barrero PR; Mistchenko AS
    Virus Res; 2008 Jul; 135(1):83-8. PubMed ID: 18400327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness evaluation of a rotavirus vaccination program in Argentina.
    Martí SG; Alcaraz A; Valanzasca P; McMullen M; Standaert B; Garay U; Lepetic A; Gomez J
    Vaccine; 2015 Oct; 33(42):5684-5690. PubMed ID: 26303875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Secondary serologic responses to dengue epidemic in 1998 in Salta, Argentina, where other flavivirus co-circulate].
    Aviles G; Rangeon G; Paz MV; Baroni P; Sabattini MS; Enría D
    Medicina (B Aires); 2001; 61(2):129-36. PubMed ID: 11374133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel vaccination approach for dengue infection based on recombinant immune complex universal platform.
    Kim MY; Reljic R; Kilbourne J; Ceballos-Olvera I; Yang MS; Reyes-del Valle J; Mason HS
    Vaccine; 2015 Apr; 33(15):1830-8. PubMed ID: 25728317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness of quadrivalent vaccine against human papilloma virus in Argentina based on a dynamic transmission model].
    Pichon-Riviere A; Alcaraz A; Caporale J; Bardach A; Rey-Ares L; Klein K; Calderón M; Augustovski F; Tatti S
    Salud Publica Mex; 2015; 57(6):504-13. PubMed ID: 26679313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.